{"title": "\u00d6sterreich | GSK", "author": null, "url": "https://www.gsk.com/en-gb/locations/austria/de-aut/", "hostname": "gsk.com", "description": "GSK Austria", "sitename": "Gsk", "date": "2023-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "In \u00d6sterreich arbeiten wir mit etwa 85 Mitarbeitern daran, ein breites Spektrum von verschreibungspflichtigen Medikamenten und Impfstoffen m\u00f6glichst vielen Menschen zug\u00e4nglich zu machen.\nIm Bereich Specialty fokussieren wir uns auf schwere Atemwegserkrankungen, Nasenpolypen sowie 2 seltene Erkrankungen. Unser monoklonaler Antik\u00f6rper gegen SARS-CoV-2 dient der Behandlung von COVID-19 bei Patienten, die ein erh\u00f6htes Risiko f\u00fcr einen schweren Verlauf aufweisen. Au\u00dferdem erforschen wir Therapieoptionen zur Behandlung von An\u00e4mie aufgrund von chronischen Nierenerkrankungen.\nMit unseren innovativen, transformativen onkologischen Therapien und Medikamenten konzentrieren wir uns darauf, die \u00dcberlebenschancen von Menschen mit Krebs zu maximieren. Unsere derzeitigen Schwerpunktbereiche sind Eierstockkrebs, Endometriumkrebs und Multiples Myelom.\nMit unserem breit gef\u00e4cherten und innovativen HIV-Portfolio setzen wir uns daf\u00fcr ein, Fortschritte bei der Behandlung von Menschen zu erzielen, die mit HIV leben oder von einer HIV-Infektion bedroht sind. Unser aktueller Schwerpunkt liegt auf 2DRs (2-Drug-Regimens) und der lang wirksamen, injizierbaren Behandlung von HIV.\nAls eines der f\u00fchrenden Impfstoffunternehmen in \u00d6sterreich und weltweit, sch\u00fctzen wir mit unserem breiten Portfolio an Impfstoffen Kinder und Erwachsene jeden Alters vor einer Vielzahl von Erkrankungen. Unsere derzeitigen Schwerpunkte sind die Pr\u00e4vention von Meningokokken-Erkrankung sowie der Schutz vor G\u00fcrtelrose. (Weitere Informationen unter\n[https://www.meningokokken-erkrankung.at/](https://www.meningokokken-erkrankung.at/) sowie unter [https://www.guertelrose-info.at/](https://www.guertelrose-info.at/).)\nMehr zu unseren pharmazeutischen Produkten und Impfstoffen finden Sie auf unserer\n[globalen Website](https://www.gsk.com/en-gb/).\nKarriere\nFinden Sie heraus, wie Sie Teil unseres Unternehmes werden k\u00f6nnen und bewerben Sie sich bei uns.\nKontakt\nGlaxoSmithKline Pharma GmbH\nWienerbergstra\u00dfe 7, 5. Stock\n1100 Wien\nTel:\n[+43 1 970 75-0 ](tel:+43197075-0)\nFax:\n[+43 1 970 75-170](tel:+43 1 970 75-170)\nEmail:\n[at.info@gsk.com](mailto:at.info@gsk.com)\nFirmenbuch: FN 115955y, Handelsgericht Wien\nUID: ATU 14215008\nNebenwirkungen melden\nTel:\n[+43 1 970 75-0](tel:+43 1 970 75-0)\nEmail:\n[arzneimittelsicherheit@gsk.com](mailto:arzneimittelsicherheit@gsk.com)\nInformationen zur Meldung von Nebenwirkungen finden Sie\n[hier](https://gskpro.com/de-at/report-adverse-event/).\nMedienanfragen\nMag. Barbara Masser-Mayerl\nCorporate Communications Lead\nTel:\n[+ 43 664 8270120](tel:+%2043 664 8270120)\nEmail:\n[at.info@gsk.com](mailto:at.info@gsk.com)\nUnsere aktuellen Presseaussendungen finden Sie\n[hier in unserem Pressroom](https://www.ots.at/pressemappe/5759/glaxosmithkline-pharma-gmbh). Aufgrund des Werbeverbotes f\u00fcr verschreibungspflichtige Arzneimittel (AMG) k\u00f6nnen wir hier keine Informationen bzw. Pressemeldungen \u00fcber unsere Produkte ver\u00f6ffentlichen. Sollten die von Ihnen gesuchten Informationen nicht dabei sein, freuen wir uns \u00fcber Ihre [Kontaktaufnahme](mailto:at.info@gsk.com).\nMedizinische Fachkreise\nAls Gesundheitsunternehmen arbeiten wir regelm\u00e4\u00dfig mit medizinischen Fachkr\u00e4ften zusammen. In all unseren Interaktionen stehen Transparenz und Integrit\u00e4t an oberster Stelle.\nAuf\n[GSKPro](https://gskpro.com/de-at/), unserem Portal f\u00fcr medizinische Fachkreise, erhalten Sie wichtige Informationen \u00fcber unsere Produkte, Zugang zu Videos und Webcasts, sowie zu Fortbildungsveranstaltungen und anderen Services von GSK.\nTransparenz\nGlaxoSmithKline (GSK), Mitglied von Transparency International \u00d6sterreich, hat bereits vor vielen Jahren eine Reihe von \u2013 gro\u00dfteils freiwilligen \u2013 Transparenzinitiativen ergriffen, die \u00fcber branchen\u00fcbliche Standards hinausgehen. Nach der Einf\u00fchrung des ersten Online-Registers f\u00fcr klinische Studienergebnisse 2004 durch GSK und der Ver\u00f6ffentlichung von Zahlungen an Patientengruppen seit 2006, werden seit 2016 j\u00e4hrlich alle geldwerten Leistungen an Angeh\u00f6rige und Institutionen der medizinischen Fachkreise \u2013 dem EFPIA Disclosure Code folgend - offengelegt.\n[Offenlegung von Zahlungen an Angeh\u00f6rige medizinischer Fachkreise in \u00d6sterreich](https://www.gsk.com/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/#tab-5795) [Unterst\u00fctzung von Patientengruppen: Umfang und Zweck der gesamten GSK-Unterst\u00fctzung f\u00fcr Patientengruppen in den letzten 3 Jahren ](/media/10119/austria-patient-organisation-funding-disclosure-2022.pdf) (PDF-84KB) [Transparenz in klinischer Forschung](https://www.gsk.com/en-gb/innovation/trials/data-transparency/)\nMitgliedschaften und Partnerschaften\nWir sind Mitglied der\n[Pharmig](https://www.pharmig.at/) (Verband der pharmazeutischen Industrie \u00d6sterreichs), des [FOPI](http://www.fopi.at/) (Forum der forschenden pharmazeutischen Industrie in \u00d6sterreich), der [WK\u00d6](https://www.wko.at/), [Transparency International Austrian Chapter](https://www.ti-austria.at/) und [respACT](https://www.respact.at/) (Austrian Business Council for Sustainable Development)\nUnseren Aktivit\u00e4ten im Bereich Lobbying- und Interessensvertretung, legen wir den Verhaltenskodex der\n[\u00d6sterreichischen Public Affairs Vereinigung (\u00d6PAV)](https://oepav.at/) zu Grunde.\nNP-AT-NA-WCNT-220003; 08/2022", "language": null, "image": "https://www.gsk.com/assets/img/GSK_Logo_Full_Colour_RGB.png?mode=pad&width=350&height=157", "pagetype": "website", "links": ["#main-content", "#header-search", "/en-gb/locations/", "https://www.gskpro.com", "/en-gb/contact-us/", "/en-gb/search/", "#", "", "/en-gb/", "/en-gb/behind-the-science-magazine/", "", "/en-gb/behind-the-science-magazine/", "/en-gb/behind-the-science-magazine/", "/en-gb/company/", "", "/en-gb/company/", "/en-gb/company/", "/en-gb/company/purpose-strategy-and-culture/", "/en-gb/company/outstanding-people/", "", "/en-gb/company/outstanding-people/", "/en-gb/company/outstanding-people/working-together/", "/en-gb/company/outstanding-people/my-gsk-story/", "/en-gb/company/outstanding-people/innovating-together-2022/", "/en-gb/company/outstanding-people/innovating-together-2021/", "/en-gb/company/gsk-at-a-glance/", "/en-gb/company/history-and-heritage/", "/en-gb/company/board-of-directors-and-leadership-team/", "/en-gb/company/board-information/", "/en-gb/company/governance/", "", "/en-gb/company/governance/", "/en-gb/company/governance/committees/", "/en-gb/company/governance/shareholders/", "/en-gb/company/governance/sarbanes-oxley-act-2002/", "/en-gb/company/governance/compliance/", "/en-gb/company/policy-positions/", "/en-gb/company/codes-standards-and-reports/", "/en-gb/company/purpose-strategy-and-culture/", "/en-gb/company/outstanding-people/", "/en-gb/innovation/", "", "/en-gb/innovation/", "/en-gb/innovation/", "/en-gb/innovation/research-and-development-approach/", "/en-gb/innovation/pipeline/", "/en-gb/innovation/therapeutic-areas/", "", "/en-gb/innovation/therapeutic-areas/", "/en-gb/innovation/therapeutic-areas/infectious-diseases/", "/en-gb/innovation/therapeutic-areas/hiv/", "/en-gb/innovation/therapeutic-areas/respiratoryimmunology/", "/en-gb/innovation/therapeutic-areas/oncology/", "/en-gb/innovation/therapeutic-areas/opportunity-driven/", "/en-gb/innovation/technologies/", "/en-gb/innovation/trials/", "", "/en-gb/innovation/trials/", "/en-gb/innovation/trials/provision-of-unlicensed-medicines-for-unmet-medical-needs/", "/en-gb/innovation/trials/data-transparency/", "/en-gb/innovation/trials/diversity-in-clinical-trials/", "/en-gb/innovation/partnerships/", "", "/en-gb/innovation/partnerships/", "/en-gb/innovation/partnerships/supported-studies/", "/en-gb/innovation/rd-locations/", "/en-gb/behind-the-science-magazine/", "/en-gb/innovation/partnerships/", "/en-gb/products/", "", "/en-gb/products/", "/en-gb/products/", "/en-gb/products/our-product-areas/", "/en-gb/products/products-a-z/", "/en-gb/innovation/", "https://gskpro.com", "/en-gb/responsibility/", "", "/en-gb/responsibility/", "/en-gb/responsibility/", "/en-gb/responsibility/access/", "/en-gb/responsibility/global-health-and-health-security/", "", "/en-gb/responsibility/global-health-and-health-security/", "/en-gb/responsibility/global-health-and-health-security/global-health/", "/en-gb/responsibility/global-health-and-health-security/health-security/", "/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/", "/en-gb/responsibility/global-health-and-health-security/improving-access-to-healthcare/", "/en-gb/responsibility/environment/", "", "/en-gb/responsibility/environment/", "/en-gb/responsibility/environment/climate/", "/en-gb/responsibility/environment/water/", "/en-gb/responsibility/environment/materials-and-waste/", "/en-gb/responsibility/environment/biodiversity/", "/en-gb/responsibility/diversity-equity-and-inclusion/", "/en-gb/responsibility/ethical-standards/", "", "/en-gb/responsibility/ethical-standards/", "/en-gb/responsibility/ethical-standards/working-with-third-parties/", "/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/", "/en-gb/responsibility/ethical-standards/human-rights/", "/en-gb/responsibility/ethical-standards/use-of-animals/", "/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/", "/en-gb/responsibility/product-governance/", "/en-gb/responsibility/charitable-investments/", "/en-gb/responsibility/esg-resources/", "", "/en-gb/responsibility/esg-resources/", "/en-gb/responsibility/esg-resources/esg-reports-archive/", "/en-gb/responsibility/diversity-equity-and-inclusion/", "/en-gb/company/policy-positions/", "/en-gb/investors/", "", "/en-gb/investors/", "/en-gb/investors/", "/en-gb/investors/why-invest-in-gsk/", "/en-gb/investors/quarterly-results/", "/en-gb/investors/financial-reports/", "", "/en-gb/investors/financial-reports/", "/en-gb/investors/financial-reports/annual-report-2022/", "/en-gb/investors/financial-reports/corporate-reports-archive/", "/en-gb/investors/environmental-social-and-governance/", "/en-gb/investors/speeches-and-presentations/", "/en-gb/investors/events-calendar/", "/en-gb/investors/dividend-and-share-price/", "", "/en-gb/investors/dividend-and-share-price/", "/en-gb/investors/dividend-and-share-price/gsk-share-price/", "/en-gb/investors/dividend-and-share-price/share-price-calculators-gbpusd/", "/en-gb/investors/dividend-and-share-price/dividend-calculators-gbpusd/", "/en-gb/investors/dividend-and-share-price/dividend-calendar/", "/en-gb/investors/analyst-consensus/", "/en-gb/investors/shareholder-information/", "", "/en-gb/investors/shareholder-information/", "/en-gb/investors/shareholder-information/manage-your-shares/", "/en-gb/investors/shareholder-information/annual-general-meeting/", "/en-gb/investors/shareholder-information/general-meeting/", "/en-gb/investors/shareholder-information/annual-governance-meeting/", "/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/", "/en-gb/investors/shareholder-information/adr-programme/", "/en-gb/investors/shareholder-information/asset-reunification-prosearch/", "/en-gb/investors/shareholder-information/share-scam-alert/", "/en-gb/investors/shareholder-information/privacy-notice-for-ordinary-shareholders/", "/en-gb/investors/shareholder-information/shareholder-faqs/", "/en-gb/investors/stock-exchange-announcements/", "", "/en-gb/investors/stock-exchange-announcements/", "/en-gb/investors/stock-exchange-announcements/london-rns/", "/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/", "/en-gb/investors/stock-exchange-announcements/new-york-sec/", "/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/", "/en-gb/investors/corporate-actions/", "", "/en-gb/investors/corporate-actions/", "/en-gb/investors/corporate-actions/consumer-healthcare-demerger/", "/en-gb/investors/corporate-actions/consumer-healthcare-joint-venture/", "/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/", "/en-gb/investors/debt-investors/", "/en-gb/investors/investor-contacts/", "/en-gb/media/press-releases/", "/en-gb/innovation/pipeline/", "/en-gb/media/", "", "/en-gb/media/", "/en-gb/media/", "/en-gb/media/press-releases/", "/en-gb/media/media-contacts/", "/en-gb/media/conferences/", "/en-gb/media/media-library/", "/en-gb/media/our-response-to-the-situation-in-ukraine/", "/en-gb/media/our-response-to-covid-19/", "/en-gb/media/social-media/", "/en-gb/media/rss-feeds/", "/en-gb/behind-the-science-magazine/", "/en-gb/media/conferences/", "/en-gb/careers/", "", "/en-gb/careers/", "/en-gb/careers/", "/en-gb/careers/search-jobs/", "/en-gb/careers/featured-careers/", "", "/en-gb/careers/featured-careers/", "/en-gb/careers/featured-careers/a-career-in-data/", "/en-gb/careers/life-at-gsk/", "", "/en-gb/careers/life-at-gsk/", "/en-gb/careers/life-at-gsk/whats-your-angle/", "/en-gb/careers/experienced-professionals/", "", "/en-gb/careers/experienced-professionals/", "/en-gb/careers/experienced-professionals/business-operations/", "/en-gb/careers/experienced-professionals/engineering/", "/en-gb/careers/experienced-professionals/manufacturing-and-supply/", "/en-gb/careers/experienced-professionals/marketing-and-sales/", "/en-gb/careers/experienced-professionals/research-and-development/", "", "/en-gb/careers/experienced-professionals/research-and-development/", "/en-gb/careers/experienced-professionals/research-and-development/chemical-manufacturing-and-controls-cmc-medicine-development-and-supply-mds/", "/en-gb/careers/experienced-professionals/research-and-development/genomic-sciences/", "/en-gb/careers/experienced-professionals/technology/", "/en-gb/careers/early-talent/", "", "/en-gb/careers/early-talent/", "/en-gb/careers/early-talent/kickstart-your-career/", "/en-gb/careers/early-talent/apprentice-programmes/", "/en-gb/careers/early-talent/work-experience-placements-and-internships/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/", "", "/en-gb/careers/early-talent/future-leaders-graduate-programme/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/business-operations/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/engineering/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/manufacturing-operations-quality-supply-chain/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/marketing-and-sales/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/research-and-development/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/technology/", "/en-gb/careers/early-talent/future-leaders-graduate-programme/manufacturing-sciences-technology/", "/en-gb/careers/early-talent/post-graduate-opportunities/", "/en-gb/careers/our-global-and-regional-hubs/", "/en-gb/careers/how-we-hire/", "", "/en-gb/careers/how-we-hire/", "/en-gb/careers/how-we-hire/frequently-asked-questions/", "/en-gb/careers/how-we-hire/fraudulent-internet-recruitment-activities/", "/en-gb/company/outstanding-people/", "/en-gb/responsibility/diversity-equity-and-inclusion/", "https://www.gskpro.com", "/en-gb/contact-us/", "/en-gb/", "/en-gb/locations/", "/en-gb/locations/austria/", null, "/en-gb/locations/austria/", "https://www.meningokokken-erkrankung.at/", "https://www.guertelrose-info.at/", "https://www.gsk.com/en-gb/", "https://jobs.gsk.com/en-gb/jobs?page=1&location=Austria&woe=12&stretchUnit=MILES&stretch=10", "tel:+43197075-0", "tel:+43 1 970 75-170", "mailto:at.info@gsk.com", "#", "tel:+43 1 970 75-0", "mailto:arzneimittelsicherheit@gsk.com", "https://gskpro.com/de-at/report-adverse-event/", "tel:+%2043 664 8270120", "mailto:at.info@gsk.com", "https://www.ots.at/pressemappe/5759/glaxosmithkline-pharma-gmbh", "mailto:at.info@gsk.com", "https://gskpro.com/de-at/", "https://www.gsk.com/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/#tab-5795", "/media/10119/austria-patient-organisation-funding-disclosure-2022.pdf", "https://www.gsk.com/en-gb/innovation/trials/data-transparency/", "https://www.pharmig.at/", "http://www.fopi.at/", "https://www.wko.at/", "https://www.ti-austria.at/", "https://www.respact.at/", "https://oepav.at/", "#", "/", "/en-gb/locations/", "/media/9966/modern-slavery-act-statement-2022.pdf", "/en-gb/locations/", "/en-gb/media/social-media/", "https://www.gskpro.com", "https://www.gsk-studyregister.com/en/", "https://supplier.gsk.com", "https://viivhealthcare.com/", "/en-gb/behind-the-science-magazine/", "/en-gb/company/", "/en-gb/innovation/", "/en-gb/products/", "/en-gb/responsibility/", "/en-gb/investors/", "/en-gb/media/", "/en-gb/careers/", "/en-gb/innovation/partnerships/", "/en-gb/contact-us/report-a-possible-side-effect/", "https://gsk.i-sight.com/landing-page/", "https://www.facebook.com/GSK", "http://twitter.com/GSK", "http://www.youtube.com/GSK", "http://www.linkedin.com/company/glaxosmithkline", "https://www.instagram.com/gsk/", "/en-gb/media/rss-feeds/", "/en-gb/accessibility/", "/en-gb/terms-of-use/", "/en-gb/cookie-policy/", "https://privacy.gsk.com/en-gb/privacy-notice/general", "/en-gb/sitemap/", null, "#"]}